Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis.
The pharmacokinetics of glycyrrhizin (G) in eight patients with chronic hepatitis receiving chronically i.v. administration of 120 mg dose of G was investigated. The plasma concentration of G in the patients after dosing declined in a monophasic manner. However, the pharmacokinetic profiles varied among patients. The mean elimination half-life (t1/2) and the total body clearance (CLtot) were 6.0 h (range 4.3-10.7 h) and 7.9 ml h-1 kg-1 (4.5-12.7 ml h-1 kg-1), respectively. The variation of the CLtot for G was closely related to that of aspartate aminotransferase (r = -0.739, p < 0.05) and alanine aminotransferase (r = -0.783, p < 0.05) activities in the plasma.
Tanaka
N
N
Department of Gastroenterology, University of Tsukuba, Ibaraki, Japan.
Yamamura
Y
Y
Santa
T
T
Kotaki
H
H
Uchino
K
K
Sawada
Y
Y
Aikawa
T
T
Osuga
T
T
Iga
T
T
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000493:pharmacokinetics*; D001219:Aspartate Aminotransferases / Q000097:blood; D002908:Chronic Disease; D005260:Female; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D019695:Glycyrrhizic Acid; D006505:Hepatitis / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D008111:Liver Function Tests; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged
D000998:Antiviral Agents; D019695:Glycyrrhizic Acid; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D006034:Glycyrrhetinic Acid